Sydney, Feb 19, 2026, 18:20 AEDT — After-hours
- Pro Medicus finished Thursday’s session 5.0% higher at A$129.16.
- Shares remain about 24% lower for the week, following a steep slide after earnings.
- The interim payout’s ex-dividend date, Feb. 26, has investors’ attention now.
Shares of Pro Medicus Ltd ASX:PME surged 5.0% to close at A$129.16 on Thursday, standing out among gainers as the S&P/ASX 200 picked up 0.88% and health care names advanced 1.73%.
That rebound stands out, with PME having swung sharply since reporting interim results last week. The stock is off 23.79% over the last seven days, and it’s still sitting nearly 61% beneath its 52-week peak of A$330.48 from July, according to data.
Up next: dividend dates. Pro Medicus is set to pay out a fully franked interim dividend of 32 Australian cents. Shares go ex-dividend on Feb. 26, so only holders before then will qualify for the payment. The record date hits Feb. 27, and the funds are scheduled to land in accounts on March 20.
Shares saw active movement Thursday, swinging from A$121.51 up to A$129.78. Roughly 654,000 shares traded hands. That followed a 2.35% slide on Wednesday, which came after a 7.69% rally the previous session, according to market data.
Shares rebounded after Pro Medicus took a sharp hit post-Dec-half results. The company posted a 28.4% jump in revenue from ordinary activities, reaching A$124.8 million. Underlying profit before tax moved up 29.7% to A$90.7 million. EBIT margin ticked higher, now at 73%. CEO Sam Hupert described the pipeline as “very strong” and pointed out seven more “go-lives” — customer deployments — are lined up by year-end. Company Announcements
Broker calls have shifted as well. Jefferies’ Wei Sim bumped Pro Medicus up to Buy from Hold, putting the target at A$155. The analyst pointed to “over 90% recurring revenue” and described the business as a capital-light model. TipRanks
Directors stepped in as the stock slid, according to recent filings. On Feb. 13, non-executive director Anthony Glenning picked up 2,080 shares at A$119.81. Deena Shiff also made a move that day, buying 788 shares at A$126.67, the disclosures show.
Still, investors keep circling back to one variable: how much valuation swings outside the main imaging unit are driving results. The interim report shows the company logged an unrealised fair value gain of roughly A$149.1 million on other financial assets during the half. That figure can move sharply along with market prices—especially the share price of 4D Medical, which is linked to its hybrid stake.
Friday’s action, along with the days ahead, puts a spotlight on PME: can shares stay above recent lows, and how will they move heading into the Feb. 26 ex-dividend date and the March 20 payout?
